Skip to main content

与抗菌素耐药性的战斗始于灿盛制药

事实:抗菌素耐药性(AMR)对全球公共健康构成越来越大的威胁。通过与我们的合作伙伴合作,我们知道这是我们可以赢得的战斗。

抗菌素耐药性不再是曾经被认为是遥远的威胁。在全球范围内,每年已经有约700,000例死亡与AMR相关。现在是采取行动的时候了:整个药品供应链必须共同努力,以解决这一日益严重的问题。

作为制药领域的全球领导者,我们确切地知道对我们的期望,并且我们对管理,治疗和处置抗生素废物的方式保持严格控制。但是我们的责任不止于此,这就是为什么我们将与AMR对抗作为组织可持续发展战略的三大核心支柱之一的原因。

我们对预防和消除AMR的承诺使我们在解决这一关键健康问题方面发挥了核心作用。在全球范围内,我们正在与整个价值链上的合作伙伴和供应商合作,帮助行业和政府的决策者改善AMR标准和政策,并在最需要的地区发展意识和最佳实践。

降低AMR的风险

工厂废水中高浓度的抗生素残留会导致耐药菌热点。作为青霉素抗生素的领导者,我们必须采取负责任的行动:通过投资最新的废水技术,我们正在采取措施避免对AMR产生影响。

同时,通过我们全公司范围内的可持续抗生素计划,我们开发了一种创新的方法来检测处理后的废水中的抗生素活性水平低至十亿分之50(相当于每1000升50毫克)。自2016年以来,这种严格的方法已在我们全球各地的工厂中应用。

在此记录的基础上,Centrient最近启动了PNEC项目,该项目旨在完全遵守AMR工业联盟制定和采用的安全排放目标。预测的无效浓度(PNEC)是指水中的抗生素浓度,在该浓度下不会对环境造成不利影响或不会产生抗药性风险。

为自己设定了在2021年前达到所有废水流(包括我们的供应商所在地)的PNEC目标值的目标,我们正按计划实现目标。实际上,Centrent最大的产品组合,即半合成青霉素API系列,已经达到了PNEC的目标。

Fact: antimicrobial resistance, or AMR, is a growing threat to public health worldwide. By working with our partners, we know it’s a battle we can win.

Antimicrobial resistance is no longer the distant threat it was once considered to be. Worldwide, approximately 700,000 deaths are already linked to AMR each year. The time for action is now: the entire pharmaceutical supply chain must work together to contain this growing issue.

As a global leader in pharmaceuticals, we know exactly what’s expected of us, and we maintain rigid control over how we manage, treat and dispose of antibiotic waste. But our responsibilities don’t end there, which is why we have made combatting AMR one of the three core pillars of our organisational sustainability strategy.

Our commitment to AMR prevention and eradication sees us play a central role in tackling this critical health issue. Globally, we are working with partners and suppliers across the value chain, helping decision-makers in industry and government to improve AMR standards and policies, and developing awareness and best practice in the regions where it’s needed most.

Lowering the risk of AMR

High concentrations of antibiotic residues in factory wastewater can lead to hotspots of resistant bacteria. As a leader in penicillin antibiotics, we must act responsibly: by investing in state-of-the-art wastewater technologies, we’re taking steps to avoid contributing to AMR.

Meanwhile, through our company-wide Sustainable Antibiotics programme, we’ve developed an innovative way of detecting antibiotic activity levels in treated wastewater as low as 50 parts per billion (equivalent to 50 mg per 1,000 litres). This rigorous method has been in place at our sites worldwide since 2016.

Building on this record, Centrient recently launched Project PNEC, designed to achieve full compliance with the safe discharge targets developed and adopted by the AMR Industry Alliance. The Predicted No-Effect Concentration (PNEC) refers to the concentration of antibiotics in water at which there are unlikely to be adverse environmental effects or risks of antimicrobial resistance developing. 

Having set ourselves the goal of meeting the PNEC target values for all wastewater streams, including at our supplier sites, by 2021, we are well on track to reach our objective. Indeed, Centrient’s largest portfolio, the Semi-Synthetic Penicillin API range, already meets the PNEC targets.